Skip to main content
ANGO logo

ANGO · Angiodynamics Inc

Track ANGO — free
$15.20 -0.27 (-1.75%) At close · Sep 4
Market Cap
$619.99M
Shares
41.33M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.20 Open$15.36 Day$14.85–15.44 52W close$9.70–16.13 Avg vol 30d404K Short int1.4M · 3.3% float · 2.5d Short vol17% Last earningsJul 14, 2026 DataJan 2020–Sep 2026 Filing10-K · Jul 14

Up next

Next earnings call
Oct 13, 2026 Est · unconfirmed · in 5 wks
filed Jul 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$320.17M
Trailing 12 months
Net income (TTM)
−$36.74M
Trailing 12 months
Revenue growth YoY
+8.0%
Year over year
Operating margin
-12.5%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
0.1%
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
+41.7%
Trailing year
Short interest
3.3%
Latest settlement · 2.5 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +4%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +42%
trailing
YTD return +18%
this year
Relative strength +27%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +31 funds added
Insider flow Distributing
Net -$344.0K over 90 days · 100% sells
Short interest Rising
3.27% of float · ▲ +10.8% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
162 holders — near 3-yr high, broad support
Squeeze score 61
elevated · 0–100
Fundamentals
Excellent
Revenue growth +10%
Y/Y
Gross margin 60%
expanding
EPS growth −6%
Y/Y
Free cash flow $508.0K
Buyback $13.3M
remaining
Balance sheet $76.1M
net cash
Quant / Vol
risk profile
Moderate
Volatility 43%
annualized · 1-yr
Max drawdown −29%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the Earnings Call filed Nov 30, 2021
Auryon revenue · fiscal 2022 $24M – $26M
Gross margins · fiscal year 2022 52% – 54%
R&D spending · fiscal year 2022 10% – 13%
SG&A spending · fiscal year 2022 40% – 45%
Net sales · fiscal year 2022 $310M – $315M
Guided vs delivered · last 1 settled
Net sales fiscal year 2022
guided $310M – $315M
$316.22M Beat +1.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $15 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +31 funds added
Insider flow Distributing
Net -$344.0K over 90 days · 100% sells
Short interest Rising
3.27% of float · ▲ +10.8% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
162 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10 Now $15 · 86% Range high $16
vs 200-day avg +24% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANGO
Angiodynamics Inc
this stock
$619.99M +18.4% +10.2% 3.3%
ISRG
Intuitive Surgical Inc
$130.62B -35.3% +20.5% 42.5 2.0%
BDX
Becton Dickinson & Co
$50.32B +8.2% 3.4%
MDLN
Medline Inc.
$48.24B -12.9% +11.5% 2.8%
ALC
Alcon Inc
$34.27B -10.5% +10.5% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
162
% held
91.9%
Net QoQ
-626.4K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
189
View
Short & Settlement
Short Interest Rising
Shares short
1.4M
Days to cover
2.5d
Change
+131.6K sh
View
Short Volume
Short vol %
17%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$22.9K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
37.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$344.0K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Debbie Wasserman Schultz
Amount
$2.0K–$2.0K
Traded
Oct 20, 2025
View
Financials
Financials
Revenue (FY)
$320.2M
Net income (FY)
$-36.7M
EPS diluted
$-0.88
View
Buybacks
Authorized
$15.0M
Remaining
$13.3M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Aug 11, 2026
This year
12
View
Proposed Sales
Value
$344.0K
Shares
23.4K
Filed
Jul 30, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 11, 2026
View

Performance

5D 20D 120D MTD YTD
ANGO -4.1% -3.1% +42.5% -5.8% +18.4%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -4.2% -2.7% +27.3% -6.2% +5.4%

Capital returns

Buyback program · as of May 31, 2026
Authorized
$15.00M
Spent (derived)
$1.70M
Remaining
$13.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1275187 CUSIP 03475V101 13F (30d) 128 filings 128 filers Visit website Investor relations